Health Effects of Increasing Muscle Activation While Sitting in Office Workers

Blood Pressure Clinical Trial

Official title:

Health Effects of Increasing Muscle Activation While Sitting in Office Workers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02855541
• Other study ID #: UColoradoBoulder
• Status: Completed
• Phase: N/A
• Start date: August 2016
• Est. completion date: June 2017

Study information

• Verified date: November 2018
• Source: University of Colorado, Boulder
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous research suggests that prolonged sitting increases risk for cardiometabolic diseases and the risk factors associated with cardiometabolic diseases. However, no study to date has examined if a chronic intervention that breaks up prolonged sitting in a real-world environment results in a reduction in the metabolic risk factors associated with cardiometabolic diseases. Thus, the objective of this study is to examine the potential health benefits of breaking up sitting bouts throughout the workday using a small cycling device (DeskCycle) in office workers involved with jobs that require prolonged bouts of sitting. The investigators hypothesize that breaking up sitting will be associated with improvements in cardiometabolic disease risk factors. More specifically, the investigators hypothesize that breaking up sitting will decrease blood glucose during an oral glucose tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure, decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol, and triglycerides.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Both males and females

• Subjects will need to be 18-55 years old

• Subjects will need to be sitting at least 6 hours/day on 5 days/week

• Subjects will need to be exercising less than 5 hour/week

Exclusion Criteria:

• Females that are pregnant or breast-feeding.

• Subjects must be free from any acute or chronic physical condition that would influence the outcome measures of the protocol. Examples include, but are not limited to advanced chronic disease states (chronic kidney, liver, heart, or lung disease), morbid obesity, emphysema, and an inability to use the legs for normal locomotion. Normality will be established on the basis of clinical history, physical exam, and vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease or symptoms of active illness will be excluded from study. Any subject with a history of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or symptoms of active illness will be excluded from study.

• Subjects will be excluded if they have a fasted blood glucose level >126 mg/dl or a systolic blood pressure >140 mmHg.

• Medical/psychiatric/sleep disorders history: any clinically significant unstable medical or psychological condition within the last year (treated or untreated).

• Drug use:

• Use of any medications, including over-the-counter and herbal products, that may affect metabolic function within 1 month prior to the study or need to use any of these medications at any time during the study (self-report by interview). Examples of potential medications that will exclude a subject include: beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV inhibitors. Note, subjects may be tested at a later date.

• Use of any investigational drug within 1 month before the study

Related Conditions & MeSH terms

• Blood Pressure

Intervention

Device:
• DeskCycle
A small cycling ergometer that can fit under a desk at the workplace.

Locations

Country	Name	City	State
United States	University of Colorado Boulder	Boulder	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Boulder

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Glucose	2-h Post Oral Glucose Tolerance Test Blood Glucose	Measured after 4 weeks
Primary	Maximum Oxygen Consumption	Maximum oxygen consumption (VO2max) will be used to determine physical fitness	Measured after 4 weeks
Secondary	Systolic Blood Pressure		Measured after 4 weeks
Secondary	HDL Cholesterol		Measured after 4 weeks
Secondary	LDL Cholesterol		Measured after 4 weeks
Secondary	Triglycerides		Measured after 4 weeks
Secondary	Lean Mass		Measured after 4 weeks
Secondary	Fat Mass		Measured after 4 weeks